Ubigene Highlights Gene Knockout Cell Line Capabilities to Help Accelerate Research Efficiency

EZ-editor™ platform, large-scale cell resources, and standardised workflows support faster and more reliable knockout model development for life science research

AUSTIN, Texas, March 18, 2026 — As CRISPR/Cas9 continues to play a growing role in life science research, the need for reliable Gene Knockout Cell Line models is increasing across gene function studies, disease mechanism research, and drug target validation. Ubigene is highlighting its integrated gene editing platform and service workflow designed to help researchers address common technical challenges in cell knockout projects more efficiently.

A stable Gene Knockout Cell Line can provide researchers with a more consistent and reproducible model for mechanistic studies and downstream validation. At the same time, generating a knockout model often involves multiple technically demanding steps, including sgRNA design, delivery optimization, single-cell cloning, genotype confirmation, and protein-level verification. These steps can extend project timelines and create additional pressure for in-house research teams.

To help solve these challenges, Ubigene has developed its proprietary EZ-editor™ platform for gene editing in cell lines. According to the company, the platform combines optimized gRNA design, editing parameter exploration across thousands of cell lines, more accurate assessment of cell pool editing efficiency, improved single-cell clone formation, and high-throughput genotype identification. Ubigene states that this platform can improve gene editing efficiency by 10–20× compared with traditional methods.

The company also emphasizes the practical value of knockout models in signaling pathway analysis, disease model development, drug target screening and validation, and studies involving antibody-dependent therapeutic mechanisms. Ubigene currently offers 8,000+ ready-to-use KO cell lines and 11,000+ in-stock cell lines through its Red Cotton OmniCell Bank, alongside custom knockout cell line services with turnaround times as fast as 4 weeks.

“Researchers need knockout models they can trust, but they also need a workflow that is efficient, practical, and reproducible,” said a Ubigene spokesperson. “By combining platform-based design, standardized validation, and broad cell line resources, we aim to make Gene Knockout Cell Line development more dependable and more accessible for research teams.”

According to Ubigene’s public service information, its knockout workflow covers project evaluation, strategy design, cell transfection, single-cell cloning, and clone validation, with standard quality control measures including PCR Testing and Sanger Sequencing. Depending on the service design, standard deliverables may include Cell Pool / Single-Cell Clone, Wild-Type Cells, and Experimental Reports. Ubigene says this workflow is designed to help laboratories reduce trial and error in sgRNA design, shorten screening timelines, and improve confidence in downstream data. The company also states that it serves researchers in 40+ countries and supports thousands of scientists and institutions with customized gene-editing solutions. In addition to its knockout cell services, Ubigene also offers CRISPR knockin services for precise genome modification, along with CRISPR library and CRISPR screening solutions to support high-throughput genetic target discovery and functional analysis.

Ubigene presents this service model as a practical option for laboratories seeking to reduce development complexity, improve experimental consistency, and move projects forward with greater efficiency across a wide range of gene editing applications.

About Ubigene

Ubigene is a biotech company focused on gene editing, cell biology technologies, and related research solutions. Its offerings include EZ-editor™ Gene Editing Cell Line Services, CRISPR-iScreen™Library Screening Services, EZ-OE™ Stable Cell Line Services, and cell resources from its Red Cotton OmniCell Bank. According to the company’s website, its mission is to “Make genome editing easier.”